Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02840721 · ClinicalTrials.gov registry record · Phase 2
Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.
A Phase 2 study of Colitis, Ulcerative, sponsored by Telavant.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 20
- Study locations
NCT02840721: Completed Phase 2 study of Colitis, Ulcerative, sponsored by Telavant.
NCT02840721 is a Phase 2 study of Colitis, Ulcerative that has completed, run by Telavant. The registered enrollment target is 50 participants, below the 404-participant average among 28 other Colitis, Ulcerative trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02840721, a Phase 2 study of Colitis, Ulcerative, has completed, sponsored by Telavant.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of PF-06480605 in subjects with moderate to severe ulcerative colitis.
Primary Outcome
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. A serious AE (SAE) was any untoward medical occurrence at any dose that (1) resulted in death; (2) was life-threatening (immediate risk of death); (3) required inpatient hospitalization or prolongation of existing hospitalization; (4) resulted in persistent or s
Conditions Studied
Interventions
- DRUG PF-06480605
Study Locations (20)
New York
- NYU Langone Long Island Clinical Research Associates - Great Neck
- NYU Langone Nassau Gastroenterology Associates - Great Neck
- New York Presbyterian Hospital-Weill Cornell Medical College - New York
- Weill Cornell Medical College - New York
- Weill Cornell Medicine - New York
- New York Presbyterian Hospital - New York
Florida
- Surgery Center of Aventura - Aventura
- Venture Ambulatory Surgical Center - North Miami Beach
- FQL Research, LLC - Pembroke Pines
Other
- UZ Leuven (University Hospital Leuven) - Pharmacy Clinical Trials - Leuven
- UZ Leuven (University Hospital Leuven) - Radiology Department - Leuven
- UZ Leuven (University Hospital Leuven), Campus Gasthuisberg - Leuven
Massachusetts
- Brigham and Women's Hospital - Boston
- Brigham and Women's Hospital - Chestnut Hill
North Holland
- Academic Medical Center, Apotheek-Kenniscentrum Geneesmiddelenonderzoek - Amsterdam
- Academic Medical Centre, Department of Radiology - Amsterdam
Wisconsin
- Allegiance Research Specialists, LLC - Wauwatosa
CZ
- AOU Mater Domini - Univ."Magna Graecia" di Catanzaro - Campus Venuta - U.O Fisiopatologia Digestiva - Catanzaro
Milan (MI)
- ISTITUTO CLINICO HUMANITAS Sezione Autonoma di Malattie Infiammatorie Croniche Intestinali - Rozzano
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2016-10-26 |
| Est. Completion | 2018-08-30 |
| Phase | Phase 2 |
What the finished NCT02840721 record still lists
NCT02840721 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 404-participant average among 28 other Colitis, Ulcerative trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Colitis, Ulcerative appearing as the primary indexed condition, and to 1 intervention - of which PF-06480605 is the first listed.
NCT02840721 names 20 study sites across 9 states, led by New York, Florida, Other.
Frequently Asked Questions
What is clinical trial NCT02840721 about?
NCT02840721 is a clinical study titled "Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.". The purpose of this study is to evaluate the safety, tolerability, and efficacy of PF-06480605 in subjects with moderate to severe ulcerative colitis.
What is the current status of trial NCT02840721?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2016-10-26. Estimated completion is 2018-08-30.
What conditions does trial NCT02840721 study?
This clinical trial studies the following conditions: Colitis, Ulcerative.
What interventions are being tested in trial NCT02840721?
The interventions under investigation include: PF-06480605 (DRUG).
Who is sponsoring clinical trial NCT02840721?
This trial is sponsored by Telavant, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02840721 being conducted?
This trial has 20 study locations across Florida, Massachusetts, New York, Wisconsin, CZ. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colitis, Ulcerative
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02840721's enrollment target sits among peer trials
50 26th of 28 higher than 3 of 28 other Colitis, Ulcerative trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colitis, Ulcerative trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
RECRUITING · Phase 2
-
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
RECRUITING · Phase 2
-
Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
ACTIVE NOT RECRUITING · Phase 2
-
VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI